BIOGEN AND DENALI TO COLLABORATE ON LRRK2 PROGRAM FOR PARKINSON?S DISEASE AND CERTAIN TV PLATFORM-ENABLED PROGRAMS FOR NEURODEGENERATIVE DISEASES
August 6, 2020 at 8:02 AM EDT
- Biogen to receive license to co-develop and co-commercialize Denali?s small molecule LRRK2 inhibitor program, expanding pipeline of potential therapies in Parkinson?s disease and other movement disorders
- Biogen to receive exclusive option rights to two programs for neurodegenerative diseases utilizing Denali?s blood-brain barrier crossing TV technology platform, including for?amyloid beta, plus right of first negotiation for two additional unnamed TV platform programs
- Denali to receive a $560 million upfront payment, a $465 million equity investment and potential milestone payments, profit sharing and royalties
BIOGEN MEDIA CONTACT: Biogen Inc. David Caouette + 617 679 4945 public.affairs@biogen.comDENALI THERAPEUTICS CONTACT: Morgan Warners (GPG) + 202 295 0124 mwarners@gpg.com |